Piramal Healthcare’s total operating income for the quarter grew by 61.5 per cent from Rs 534.7 crores in Q2 FY2012 to Rs 863.5 crores in Q2 FY2013. Operating Profit (OPBITDA) for the quarter grew by 171.1 per cent to Rs 73.7 crores over Q2 FY2012. Similarly, the operating profit margin for the quarter was at 8.5 per cent as compared to 5.1 per cent in Q2 FY2012. Q2 FY2013 results also include the financial results of Decision Resources Group Inc. (DRG) that was acquired in June 2012 and of NCE R&D unit which was de-merged from Piramal Life Sciences into PEL in FY2012.
For Q2 FY2013, Pharma Solutions (CRAMS) business registered growth of 19.6 per cent with sales of Rs 364.9 crores as compared to Rs 305.1 crores in Q2 FY2012. The revenues from Indian facilities were Rs 191.9 crores as compared to Rs 187.4 crores during the same period in last quarter. Sales from facilities outside India grew by 47.0 per cent to Rs 173.0 crores over Q2 FY2012.
Piramal Critical Care sales grew by 69.8 per cent to Rs 155.5 crores over Q2 FY2012. Sales growth was primarily driven by increased sales of Sevoflurane across markets. PEL has commenced sales in two countries in EU and on schedule for launch in other major European markets over the next two quarters.
EP News Bureau